Resource Summary Report

Generated by T1D on Aug 13, 2026

Thermo Fisher: Invitrogen: Countess II Automated Cell Counter

RRID:SCR_025370
Type: Tool

Proper Citation

Thermo Fisher: Invitrogen: Countess II Automated Cell Counter (RRID:SCR_025370)

Resource Information

URL: https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/resources/resources-countess-ii.html

Proper Citation: Thermo Fisher: Invitrogen: Countess II Automated Cell Counter (RRID:SCR_025370)

Description: Fully automated cell counter and assay platform that uses optics and image analysis algorithms to analyze trypan blue-stained cells in suspension. Benchtop device that measures cell concentration and viability.

Synonyms: Countess II Automated Cell Counter

Resource Type: instrument resource

Keywords: cell counter, automated cell counter, assay platform, nalyze trypan blue-stained cells in suspension,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_025370.pdf

Resource Name: Thermo Fisher: Invitrogen: Countess II Automated Cell Counter

Resource ID: SCR_025370

Alternate IDs: Model_Number_Countess_II

Alternate URLs: https://assets.thermofisher.com/TFS-Assets/BID/manuals/MAN0014293_Countess_II_Automated_Cell_Counter_UG.pdf

Record Creation Time: 20240524T053223+0000

Record Last Update: 20260808T190716+0000

Ratings and Alerts

No rating or validation information has been found for Thermo Fisher: Invitrogen: Countess II Automated Cell Counter.

No alerts have been found for Thermo Fisher: Invitrogen: Countess II Automated Cell Counter.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at T1D .

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Renatino Canevarolo R, et al. (2025) Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Research square.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science advances, 11(29), eadw5228.

Piccoli M, et al. (2025) Direct Current Stimulation (DCS) Modulates Lipid Metabolism and Intercellular Vesicular Trafficking in SHSY-5Y Cell Line: Implications for Parkinson's Disease. Journal of neurochemistry, 169(2), e70014.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. Molecular cancer therapeutics, 24(9), 1415.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine, 6(3), 101977.

Nelson AJ, et al. (2025) Lung-resident memory B cells maintain allergic IgE responses in the respiratory tract. Immunity, 58(4), 875.

Mattavelli G, et al. (2025) A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer. Immunity.

MacMillan AC, et al. (2025) PRPS activity tunes redox homeostasis in Myc-driven lymphoma. Redox biology, 84, 103649.

Murphy KC, et al. (2025) MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer research, 85(22), 4359.

Alam A, et al. (2022) Fungal ablation and transplantation of specific fungal species into PDAC tumor-bearing mice. STAR protocols, 3(3), 101644.

Governa P, et al. (2018) Effects of Boswellia Serrata Roxb. and Curcuma longa L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2. Pharmaceuticals (Basel, Switzerland), 11(4).